Medications for Hiv Nonprogressors

25 results

  • atripla access

    (EFAVIRENZ, EMTRICITABINE, and TENOFOVIR DISOPROXIL FUMARATE)
    Gilead Sciences Inc
    ATRIPLA™ is indicated for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 40 kg, either as a complete regimen or in combination with other antiretroviral agents.

  • complera access

    (EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, and TENOFOVIR DISOPROXIL FUMARATE)
    Gilead Sciences Inc
    COMPLERA™ is indicated for the treatment of HIV-1 infection in adults and pediatric patients (≥35 kg), either as initial therapy for those with baseline HIV-1 RNA ≤100,000 copies/mL or to replace a stable regimen in patients who are virologically suppressed with no treatment failures.

  • emtricitabine and tenofovir disoproxil fumarate

    (Emtricitabine and tenofovir disoproxil fumarate)
    NorthStar RxLLC
    Emtricitabine and tenofovir disoproxil fumarate are indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents for adults and children (≥17 kg). They are also used for HIV-1 pre-exposure prophylaxis (PrEP) in at-risk patients (≥35 kg) to reduce sexually acquired HIV-1 infection risk.

  • emtricitabine and tenofovir disoproxil fumarate

    (Emtricitabine and tenofovir disoproxil fumarate)
    American Health Packaging
    Emtricitabine and tenofovir disoproxil fumarate are indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents in adults and children over 17 kg, and for pre-exposure prophylaxis (PrEP) in at-risk adolescents and adults weighing at least 35 kg.

  • emtricitabine and tenofovir disoproxil fumarate

    (EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE)
    DIRECT RX
    Emtricitabine and tenofovir disoproxil fumarate tablets are indicated for the treatment of HIV-1 infection in conjunction with other antiretroviral agents, and for pre-exposure prophylaxis (PrEP) in at-risk adults and adolescents, provided they weigh at least 35 kg and have a negative HIV-1 test prior to initiation.

  • emtricitabine and tenofovir disoproxil fumarate

    (Emtricitabine and Tenofovir Disoproxil Fumarate)
    Amneal Pharmaceuticals NY LLC
    Emtricitabine and tenofovir disoproxil fumarate tablets are indicated for the treatment of HIV-1 infection in adults and pediatric patients (≥17 kg) and for pre-exposure prophylaxis (PrEP) in at-risk adolescents and adults (≥35 kg) to reduce the risk of sexually acquired HIV-1 infection.

  • emtricitabine and tenofovir disoproxil fumarate

    (Emtricitabine and Tenofovir Disoproxil Fumarate)
    Amneal Pharmaceuticals NY LLC
    Emtricitabine and tenofovir disoproxil fumarate are indicated for the treatment of HIV-1 infection in adults and pediatric patients (≥17 kg) and for pre-exposure prophylaxis (PrEP) in at-risk adults and adolescents (≥35 kg) to reduce the risk of sexually acquired HIV-1 infection.

  • emtricitabine and tenofovir disoproxil fumarate

    (Emtricitabine and tenofovir disoproxil fumarate)
    NuCare Pharmaceuticals,Inc.
    Emtricitabine and tenofovir disoproxil fumarate are indicated for the treatment of HIV-1 infection in adults and pediatric patients (≥17 kg) and for pre-exposure prophylaxis (PrEP) in at-risk individuals (≥35 kg) to reduce the risk of sexually acquired HIV-1.

  • emtriva

    (EMTRICITABINE)
    Gilead Sciences Inc
    EMTRIVA® is indicated for the treatment of HIV-1 infection, used in combination with other antiretroviral agents.

  • emtriva

    (emtricitabine)
    Excella GmbH
    EMTRIVA® is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents. It should not be used with ATRIPLA®, TRUVADA®, or lamivudine-containing products. Treatment in experienced patients should be guided by lab testing and treatment history.